Stock CDXC CHROMADEX CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Chromadex Corp OTC Bulletin Board

Equities

CDXC

US1710771007

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Chromadex Corp
05-08 Transcript : ChromaDex Corporation, Q1 2024 Earnings Call, May 08, 2024
05-08 Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q1 Revenue $22.2M, vs. Street Est of $23.6M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ChromaDex Corporation Reports First Quarter 2024 Financial Results
BU
ChromaDex's NIAGEN, the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar Cellular Nutrition Cellular Energy Supplement
AQ
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
BU
ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
AQ
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
BU
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market
AQ
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BU
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
BU
ChromaDex Announces Tru Niagen is Now Third-Party Verified through the Alkemist Assured Transparency Program
AQ
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
BU
ChromaDex : March 2024 Investor Presentation
PU
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
BU
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
BU
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024
AQ
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
BU
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
BU
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen
AQ
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
BU
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
BU
ChromaDex - Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia Patients
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CDXC Stock
  4. CDXC Stock
  5. News Chromadex Corp
  6. Press Releases